What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Gene
Her main research concerns Internal medicine, Ipilimumab, Melanoma, Surgery and Immunology.
Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Oncology.
Her Ipilimumab study integrates concerns from other disciplines, such as Advanced melanoma, Clinical trial, Adverse effect, Randomized controlled trial and Nivolumab.
Michele Maio is interested in Vemurafenib, which is a branch of Melanoma.
Michele Maio interconnects Tremelimumab, Placebo and Hazard ratio in the investigation of issues within Surgery.
She has researched Immunology in several fields, including Cancer and Cancer research.
Her most cited work include:
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (5698 citations)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (4552 citations)
- Nivolumab in previously untreated melanoma without BRAF mutation. (3334 citations)
What are the main themes of her work throughout her whole career to date?
Her primary scientific interests are in Internal medicine, Melanoma, Oncology, Ipilimumab and Immunology.
Michele Maio has included themes like Gastroenterology and Surgery in her Internal medicine study.
Her Surgery research includes themes of Placebo and Hazard ratio.
Her Melanoma study combines topics from a wide range of disciplines, such as Stage and Adjuvant.
Her work in Oncology addresses issues such as Tremelimumab, which are connected to fields such as Durvalumab.
Her studies deal with areas such as Expanded access, Metastatic melanoma, Clinical trial, Advanced melanoma and Randomized controlled trial as well as Ipilimumab.
She most often published in these fields:
- Internal medicine (47.88%)
- Melanoma (35.14%)
- Oncology (34.20%)
What were the highlights of her more recent work (between 2016-2021)?
- Internal medicine (47.88%)
- Oncology (34.20%)
- Ipilimumab (28.30%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Internal medicine, Oncology, Ipilimumab, Melanoma and Nivolumab.
Her research investigates the connection with Internal medicine and areas like Placebo which intersect with concerns in Surgery, Pembrolizumab, Discontinuation, Quality of life and Survival analysis.
Michele Maio combines subjects such as Mesothelioma, Immunology, Disease, Biomarker and Immunotherapy with her study of Oncology.
Her work deals with themes such as Gastroenterology, Adverse effect, Randomized controlled trial and Adjuvant therapy, which intersect with Ipilimumab.
The study of Melanoma is intertwined with the study of Clinical trial in a number of ways.
Her Nivolumab research focuses on Phases of clinical research and how it relates to Incidence and Prostate cancer.
Between 2016 and 2021, her most popular works were:
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (1975 citations)
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma (879 citations)
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study (665 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
